
CLPD Basic







The CLPD Basic is a specialized test that helps identify disorders affecting lymphocytes, white blood cells that play a crucial role in the immune system. It detects changes that may indicate chronic lymphoproliferative disorders or leukemia, helping doctors diagnose, classify, and monitor the disease for accurate treatment planning.









Understanding CLPD Basic
CLPD (Chronic Lymphoproliferative Disorder) is a group of disorders characterized by the abnormal growth of lymphocytes, a type of white blood cell that helps the body fight infections. In some cases, CLPD may progress into leukemia, a cancer of the blood and bone marrow. Early detection and precise classification are essential for proper management and treatment.
The CLPD Basic uses flow cytometry to analyze multiple cell surface markers, including CD5, CD10, CD19, CD20, CD23, CD38, FM7, Kappa, Lambda, CD100, and others. Each marker provides information about the type and maturity of lymphocytes, helping doctors identify different subtypes of leukemia or lymphoproliferative disorders.
Doctors may recommend the CLPD Basic test for CLPD, Blood for patients who show symptoms such as unexplained fatigue, fever, weight loss, or frequent infections, or when there is a suspicion of leukemia or another blood disorder. It is also advised for patients undergoing treatment for leukemia to monitor progress, assess treatment effectiveness, and track disease progression. This test helps doctors identify specific types of white blood cells, diagnose different forms of leukemia, and guide personalized management decisions, making it essential for individuals whose medical history, symptoms, or blood test results indicate a possible lymphoproliferative disorder or leukemia.
For this test, it is important to submit the clinical history, histopathology report, previous test results, and a doctor’s prescription at the time of sample collection. The Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled and submitted.
Lab test results may vary across different laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for proper understanding of the test results.
What does CLPD Basic measure?
The CLPD Basic measures multiple cell surface markers (antigens) on white blood cells to detect abnormal patterns in lymphocyte populations. It uses Flow Cytometry, a technique that evaluates the physical and chemical characteristics of cells in a fluid as they pass through lasers. This allows the test to determine the type of cells, their number, size, shape, and the presence of specific surface markers.
In the context of CLPD, Flow Cytometry helps identify whether the disorder involves B-cells, T-cells, or other lymphocyte types, and analyzes markers such as CD5, CD10, CD19, CD20, CD23, CD38, FM7, Kappa, Lambda, CD100, among others. These markers provide important information for classifying the type of lymphoproliferative disorder, assessing its aggressiveness, and differentiating between various forms of leukemia. By combining cell counts, physical characteristics, and marker expression, this test enables doctors to diagnose the disorder accurately, monitor treatment response, and guide personalized therapy decisions.





FAQs related to CLPD Basic
- Okaly GV, Nargund AR, E V, Jayanna PK, Juvva CR, Prabhudesai S. Chronic lymphoproliferative disorders at an Indian tertiary cancer centre - the panel sufficiency in the diagnosis of chronic lymphocytic leukaemia. J Clin Diagn Res. 2013 Jul;7(7):1366-71. [Accessed 13 Oct. 2025]. Available from:
- Sheikh S, Jahangir S, Khan S, Ahmed I. Chronic Lymphoproliferative Disorder of Natural Killer Cells: A Rare Event. Cureus. 2020 Sep 10;12(9):e10353. [Accessed 13 Oct. 2025]. Available from:
- Gross Z, Veyrat-Masson R, Grange B, Huet S, Verney A, Traverse-Glehen A, Ruminy P, Baseggio L. Diagnosis of chronic B-cell lymphoproliferative disease in peripheral blood = how machine learning may help to the interpretation of flow cytometry data. Hematol Oncol. 2024 Jan;42(1):e3245. [Accessed 13 Oct. 2025]. Available from:
Other tests
- CBC (Complete Blood Count)
- CRP (C-Reactive Protein), Quantitative
- Complete Hemogram (CBC & ESR)
- Serum Ferritin
- ESR (Erythrocyte Sedimentation Rate)
- Blood Group ABO & Rh Factor
- Hb (Hemoglobin)
- PT INR (Prothrombin Time with INR)
- HIV 1 and 2 Antibody, Rapid Screening Test
- Viral Marker Screening (HIV, HBsAg, Anti-HCV)
- CBC (Complete Blood Count)
- FBS (Fasting Blood Sugar)
- Thyroid Profile Total (T3, T4 & TSH)
- HbA1c (Glycosylated Hemoglobin)
- PPBS (Postprandial Blood Sugar)
- Lipid Profile
- Vitamin D (25-Hydroxy)
- Urine R/M (Urine Routine & Microscopy)
- Coronavirus Covid -19 test- RT PCR
- LFT (Liver Function Test)
- KFT (Kidney Function Test)
- TSH (Thyroid Stimulating Hormone) Ultrasensitive
- ESR (Erythrocyte Sedimentation Rate)
- Uric Acid, Serum
- Vitamin B12
- CRP (C-Reactive Protein), Quantitative
- Urine C/S (Urine Culture and Sensitivity)
- Serum Electrolytes
- Serum Calcium
- Serum Creatinine
- Diabetes Screening (HbA1C & Fasting Sugar)
- KFT with Electrolytes (Kidney Function Test with Electrolytes)
- Cholesterol - Total
- Hb (Hemoglobin)
- Complete Hemogram (CBC & ESR)














